Introducing

Learn about Remedisc

Remedisc is a synthetic 7-amino acid peptide that binds to and induces down regulation of Transforming Growth Factor Beta 1 (TGFβ1), which is often highly expressed in the degenerated discs of patients with lower back pain. Abnormal TGFβ1 signaling is associated with the degradation of extracellular matrix components that maintain the structural integrity of healthy spinal discs. TGFβ1 is also reported to stimulate the expression of nerve growth factor leading to an increase in sensory neurons and discogenic pain. Intradiscal injection of Remedisc in patients with degenerative disc disease was developed as a first-in-class approach to treating chronic back pain and disability, possibly preventing progression of disc degeneration through TGFβ1 modulation.

Reduce Back Pain

Reduce Back
Pain

Restore Function Resulting from Pain-Related Disability

Restore Function Resulting from Pain-Related Disability

Remove TheNeed for Opioids

Remove The
Need for Opioids

Research

Learn about Remedisc

More than a decade of research

Based on more than a decade of research, this novel therapeutic formulation has the potential to improve the lives of millions of people who suffer from chronic low back pain and pain-related disability caused by degenerative disc disease (DDD). Learn more about DDD here.

Remedisc contains a chemically synthesized peptide compound that modulates, in a concentration-dependent manner, the overexpression of Transforming Growth Factor Beta 1 (TGF-β1), an inflammatory cytokine which is known to play a critical role in intervertebral disc degeneration. In preclinical studies, Remedisc demonstrates robust anti-inflammatory, anti-catabolic, and pro-anabolic effects. The science behind Remedisc has been studied in extensive in vivo, animal and human clinical studies. (1) (2)

The clinical experience with Remedisc offers exciting hope to millions of chronic low back pain sufferers. We hope to share more data with you as it becomes available.

(1) Kwon, Y. J., Lee, J. W., Moon, E. J., Chung, Y. G., Kim, O. S., & Kim, H. J. (2013). Anabolic Effects of Peniel 2000, a Peptide That Regulates TGF-β1 Signaling on Intervertebral Disc Degeneration. Spine, 38(2), E49–E58. https://doi.org/10.1097/brs.0b013e31827aa896

 

(2) Kwon, Y. J., Kim, E. S., Kim, S. M., Park, H., Byun, H. M., & Nam, S. Y. (2015). Intradiscal Injection of YH14618, a First-in-Class Disease-Modifying Therapy, Reduces Pain and Improves Daily Activity in Patients with Symptomatic Lumbar Degenerative Disc Disease. The Spine Journal, 15(10), S119. https://doi.org/10.1016/j.spinee.2015.07.093

 

Request Information


Please tell us who you are, thanks.
Please let us know your name.
Please let us know your email address.

0/200

Text messaging only, no special coding please.

For information on our Privacy Policy.

Are you a robot?

Request Information

Please complete the form below to be updated on Spine Biopharma

Please tell us who you are, thanks.
Please let us know your name.
Please let us know your email address.

0/200

Text messaging only, no special coding please.

For information on our Privacy Policy.

Are you a robot?